Data from the TALENTACE trial add to growing evidence supporting the combination of immunotherapy plus anti-VEGF component with TACE

Despite greater attention being given to treatment effects on patient wellbeing, the high heterogeneity of methodologies still limits the usefulness of QoL assessment

Encouraging data were presented for FGF19-positive tumours and those with worse hepatic function, performance status or advanced vascular invasion

Preliminary results revealed that the combination of claudin 18.2/4-1BB bispecific antibody with nivolumab and mFOLFOX was also well tolerated

A system integrating computer tomography scans and pathological markers offers promise to personalise adjuvant therapy

Reduced-dose chemoradiotherapy and non-surgical strategies show promising outcomes with fewer long-term side-effects in lower gastrointestinal cancers

Findings from a small study support a non-surgical and tumour-agnostic approach with immunotherapy, but further research is needed

Data from new clinical trials reported positive results of radioligand therapy over everolimus and sunitinib, and explore the combination of everolimus and somatostatin analogues

Study confirms favourable safety profiles and encouraging efficacy of an anti-claudin 18.2 antibody-drug conjugate